Optimal Lymphadenectomy in Patients with Well-Differentiated Nonfunctioning Pancreatic Neuroendocrine Neoplasms.
lymph node dissection
nonfunctioning pancreatic neuroendocrine neoplasms
surgical resection
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Oct 2023
26 Oct 2023
Historique:
received:
30
09
2023
revised:
23
10
2023
accepted:
25
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
This study aimed to evaluate the optimal extent of lymphadenectomy in patients with nonfunctioning pancreatic neuroendocrine neoplasms. We retrospectively analyzed the clinicopathological data of patients with nonfunctioning pancreatic neuroendocrine neoplasms who underwent surgical resection. We investigated the frequency of metastases at each lymph node station according to tumor location and analyzed the factors contributing to poor overall survival (OS) and disease-free survival (DFS). Overall, data of 84 patients were analyzed. Among patients with pancreatic head tumors, metastases at stations 8, 13, and 17 were found in one (3.1%), four (12.5%), and three (9.3%) patients, respectively. However, none of the other stations showed metastases. For pancreatic body and tail tumors, metastases only at station 11 were found in two (5.1%) patients. Additionally, multivariate DFS and OS analyses showed that lymph node metastasis was the only independent prognostic factor. In conclusion, lymph node metastasis near the primary tumor was the only independent factor of poor prognosis in patients with nonfunctioning pancreatic neuroendocrine neoplasms after undergoing curative surgery. Peri-pancreatic lymphadenectomy might be recommended for nonfunctioning pancreatic neuroendocrine neoplasms.
Identifiants
pubmed: 37959242
pii: jcm12216778
doi: 10.3390/jcm12216778
pmc: PMC10647402
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pancreas. 2020 Jan;49(1):1-33
pubmed: 31856076
Neuroendocrinology. 2019;108(3):161-171
pubmed: 30481765
Neuroendocrinology. 2012;95(2):120-34
pubmed: 22261872
Br J Surg. 2021 Jul 23;108(7):811-816
pubmed: 33724300
Medicine (Baltimore). 2020 Jun 12;99(24):e20324
pubmed: 32541455
J Endocrinol Invest. 2022 Apr;45(4):705-718
pubmed: 34773595
Pancreas. 2013 May;42(4):557-77
pubmed: 23591432
HPB (Oxford). 2018 Mar;20(3):251-259
pubmed: 28988702
Ann Surg Oncol. 2017 Apr;24(4):1127-1133
pubmed: 27822631
Anticancer Res. 2022 May;42(5):2797-2801
pubmed: 35489738
Eur J Surg Oncol. 2014 Nov;40(11):1564-71
pubmed: 25086992
Br J Surg. 2016 Feb;103(3):226-32
pubmed: 26511392
Ann Surg Oncol. 2018 Aug;25(8):2467-2474
pubmed: 29789972
J Gastroenterol. 2021 Nov;56(11):1033-1044
pubmed: 34586495
JAMA Surg. 2013 Oct;148(10):932-9
pubmed: 23986355
Ann Surg Oncol. 2021 Mar;28(3):1614-1624
pubmed: 32720049
Br J Surg. 2014 Oct;101(11):1405-12
pubmed: 25132004
Surg Today. 2022 Sep;52(9):1307-1312
pubmed: 35182251
J Gastrointest Surg. 2010 Mar;14(3):541-8
pubmed: 19997980
Surgery. 2014 Sep;156(3):591-600
pubmed: 25061003
Neuroendocrinology. 2017 Feb 25;105(3):255-265
pubmed: 28237989
Sci Rep. 2018 May 8;8(1):7271
pubmed: 29739948
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702
pubmed: 29891520
Arch Surg. 2003 Aug;138(8):859-66
pubmed: 12912744
Curr Oncol. 2021 Aug 11;28(4):3071-3080
pubmed: 34436034
Ann Surg. 2008 Mar;247(3):490-500
pubmed: 18376195
Surg Today. 2019 Jul;49(7):593-600
pubmed: 30838442
BMC Endocr Disord. 2020 Apr 3;20(1):44
pubmed: 32245472
Ann Surg Oncol. 2013 Sep;20(9):2815-21
pubmed: 23771245
Eur J Surg Oncol. 2018 Jun;44(6):778-783
pubmed: 29610023